Campbell Shannon 4

What Happened

• Shannon Campbell, a director of Zentalis Pharmaceuticals (ZNTL), received an award of 114,200 restricted stock units (RSUs) on May 26, 2026. The grant is reported as an acquisition (award) at $0.00 per share (no cash payment reported).
• RSUs represent the right to receive shares of common stock upon vesting; this is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-26; filing date: 2026-05-27 (Form 4 filed the next day).
• Amount: 114,200 RSUs; reported price: $0.00 (award/grant).
• Vesting: One-third of the RSUs vest on each of the first, second and third anniversaries of the grant date, subject to continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding sale, or late filing noted in the disclosed information.

Context

• This is a routine director compensation grant under Zentalis’s Non-Employee Director Compensation Program. Such awards are common for non-employee directors and are compensation rather than a direct market signal to buy or sell shares.
• RSUs only convert into actual shares as they vest; until vesting, they do not represent immediately tradable stock.